CTA Success

CoED Biosciences is proud to announce the successful completion of Phase 2 of the Cancer Tech Accelerator (CTA).

As one of the select teams chosen for this prestigious programme—backed by Cancer Research UK (CRUK), Roche, and Capital Enterprise—we have spent the last six months pitching CoED Biosciences and our mission to improve cancer treatment to peers and investors.

Support from the CTA has been instrumental in advancing our mission to democratise access to life-saving treatments. With the grant funding and expert mentorship provided during Phase 2, we have accelerated the development of our automated cell separation technology, designed to make tumour-targeted CAR-T cell therapies significantly faster and more affordable to manufacture.

This milestone marks a pivotal moment in our growth. Having graduated from the CTA, we are now poised to take our technology to the next level as we enter the final phase of the Future Medicines Accelerator in 2026.

About the Cancer Tech Accelerator: The CTA is a leading UK programme dedicated to spinning out original research into commercially viable startups that can improve the early detection, diagnosis, and treatment of cancer.